Amarin's Vazkepa secures NICE recommendation
It is the first treatment in its class to receive NICE approval for cardiovascular risk reduction - News - PharmaTimes
Stay updated with breaking news from Amarin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
It is the first treatment in its class to receive NICE approval for cardiovascular risk reduction - News - PharmaTimes
A week of pupusas, sashimi, jerk chicken and more.
UK's NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated
Wall Street analysts expect Amarin Co. plc (NASDAQ:AMRN – Get Rating) to post sales of $104.88 million for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Amarin’s earnings. The lowest sales estimate is $84.65 million and the highest is $122.00 million. Amarin reported sales of $154.49 million in the […]
>> reporter: nothing but shifting narratives when it comes to state and local law enforcement and the information they provided. it doesn't appear we're getting any closer to getting the texas dps report. we were expecting it on friday. it snefr happened. at this point officials are not answering our questions. they're avoiding them all together. when i reached the local district attorney here by phone, she hung up on me, saying she wouldn't be commenting on the case at all. last week when texas dps stopped taking the media's questions, they put any inquiries towards busby but now she's not ta...